Video

Dr. Coleman on Recent Advancements Made in Cervical Cancer Treatment

Robert L. Coleman, MD, FACOG, FACS, discusses recent advancements made in the cervical cancer space.

Robert L. Coleman, MD, FACOG, FACS, chief scientific officer, The US Oncology Network, discusses recent advancements made in the cervical cancer space.

In the recurrent space, or locally advanced cervical cancer that is not amenable to curative surgery, radiation, or the combination, investigators are channeling their efforts into drug development, says Coleman. One of the most prevalent first advances observed in cervical cancer is that investigators were able to augment the effect of chemotherapy by using antiangiogenesis-based therapies; this research led to an FDA approval. That approach increased not only progression-free survival, but overall survival as well in this patient population; that was a major advance, says Coleman.

Most recently, in 2018, the space saw the FDA approval of pembrolizumab (Keytruda) FDA for use in patients with PD-L1—positive, recurrent cervical cancer. The decision was based on data from the phase 2 KEYNOTE-158 trial, which evaluated pembrolizumab in patients with multiple types of advanced solid tumors who progressed on standard-of-care therapy. At a median follow-up of 10.2 months, the median objective response rate (ORR) was 12.2% (95% CI, 6.5%-20.4%), with 3 complete and 9 partial responses. All 12 responses were in patients with PD-L1–positive tumors, for an ORR of 14.6% (95% CI, 7.8%-24.2%). The median duration of response (DOR) was not reached (range, ≥ 3.7-≥ 18.6 months).

Although the response rates are quite low, the DOR observed in that patient subgroup was actually quite long, notes Coleman. That was a really important advancement in the field. By continuing to examine novel combinations and other modalities, investigators are trying to leverage the immune system even more effectively, concludes Coleman.

Related Videos
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie